Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Connect Biopharma Holdings (CNTB) Current Assets (2023 - 2025)

Connect Biopharma Holdings (CNTB) has disclosed Current Assets for 3 consecutive years, with $50.9 million as the latest value for Q4 2025.

  • Quarterly Current Assets fell 47.47% to $50.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $50.9 million through Dec 2025, down 47.47% year-over-year, with the annual reading at $50.9 million for FY2025, 47.47% down from the prior year.
  • Current Assets hit $50.9 million in Q4 2025 for Connect Biopharma Holdings, down from $62.6 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $122.6 million in Q4 2023 to a low of $50.9 million in Q4 2025.
  • Historically, Current Assets has averaged $83.1 million across 3 years, with a median of $82.8 million in 2025.
  • Biggest five-year swings in Current Assets: decreased 20.88% in 2024 and later plummeted 47.47% in 2025.
  • Year by year, Current Assets stood at $122.6 million in 2023, then fell by 20.88% to $97.0 million in 2024, then tumbled by 47.47% to $50.9 million in 2025.
  • Business Quant data shows Current Assets for CNTB at $50.9 million in Q4 2025, $62.6 million in Q3 2025, and $77.8 million in Q2 2025.